Mirtazapine Ratiopharm

Mirtazapine, the active ingredient in Mirtazapine Ratiopharm, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a tablet for oral use. It treats major depressive disorder in adults.

GNH USA supplies Mirtazapine Ratiopharm as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a NaSSA antidepressant indicated for depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Depressive episodes associated with chronic illness: helps alleviate mood disturbances when depression co‑exists with other medical conditions. - Treatment‑resistant depression (as adjunct): may be added when first‑line agents have not achieved sufficient response.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Hepatic dysfunction - Suicidal thoughts or behavior - Severe hypotension - Allergic reactions such as Stevens‑Johnson syndrome

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

- Hepatic function: assess liver enzymes and adjust if impairment is present. - Weight monitoring: track body weight due to potential increase. - Cardiovascular disease: use caution in patients with existing heart conditions. - Concomitant CNS depressants: avoid excessive sedation when combined. - Discontinuation: taper gradually to reduce withdrawal symptoms. - Store at room temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): may precipitate serotonin syndrome. - Alcohol or CNS depressants: can intensify sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): may increase mirtazapine plasma levels. - Carbamazepine or other enzyme inducers: may reduce therapeutic effectiveness.